| Outcome Measures: |
Primary: Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast), Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin, pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15|The area under the serum concentration-time curve from time zero to 28 hours after administration (AUC 0-28hr), Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin, pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15|The area under the serum concentration-time curve from time zero to infinity (AUCinf), Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin, pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15|The observed maximum serum concentration following drug administration (Cmax), Blood samples will be collected on days 1 through 3 and then on Day 15 for the determination of serum concentrations of serelaxin, pre-treatment, 15 min, 1, 2, 3, 4, 4:15, 5, 6, 7, 8, 9, 10, 12, 24, 28, 36, 48 hours and day 15 | Secondary: Percentage of patients with reported adverse events, serious adverse events and death., From Day -21 to Day 15|Percentage of patients developing anti-RLX030 antibodies, Day 1 (pre-treatment) and Day 15
|
